Clinical Policy: Spinal Cord Stimulation

Reference Number: CP.MP.117 [Coding Implications](#Coding_Implications)

Last Review Date: 04/19

[Revision Log](#Revision_Log)

**See** [Important Reminder](#Important_Reminder) **at the end of this policy for important regulatory and legal information.**

# Description

The dorsal column stimulator (DCS), or spinal column stimulator (SCS) is a device that allows for electrical stimulation of the dorsal aspect of the spinal cord nerves in an effort to relieve pain in patients with a variety of chronic pain disorders. In most cases, neuropathic pain responds poorly to standard pharmacological and surgical therapies and can last indefinitely with increasing severity over time. It may result in severe disability. Stimulation in this area interferes with the conduction of pain impulses through adjacent sensory pathways and may stimulate endorphins. The technique does not alter the underlying pathological process. However, in selective patients with persistent and intractable pain of nerve origin, approximately 50 percent of patients will have pain relief, thereby decreasing the need for analgesic medication and at times obviating the need for further surgical procedures.

## Policy/Criteria

1. It is the policy of health plans affiliated with Centene Corporation® that spinal cord stimulation (SCS) is **medically necessary** for the following indications:
2. A *trial of SCS* for *failed back surgery syndrome* when all the following criteria are met:
3. Prior lumbar surgery;
4. Neuropathic pain lasting ≥ 6 months, is refractory and interferes with activities of daily living (ADLs);
5. Not a candidate for additional surgery;
6. Failure of≥ 6 months of conventional multidisciplinary medical therapy including all of the following:
7. Chiropractic, physical therapy or prescribed home exercise program;
8. NSAIDs (non-steroidal anti-inflammatory drugs) unless contraindicated or not tolerated;
9. Activity modification;
10. Has demonstrated cognitive ability to manage stimulator;
11. No inadequately treated major psychiatric disorders;
12. Willingness to cease any inappropriate drug use prior to implantation.
13. A *trial of SCS* for *complex regional pain syndrome* (CRPS) when all the following criteria are met:
14. Pain is being managed by a pain management specialist with experience treating CRPS and pain/burning has persisted for > 6 months;
15. Has ≥ 2 of the following symptoms limited to one extremity only:
16. Allodynia (pain sensation in response to a typically non-painful stimulus) or hyperalgesia;
17. Swelling/tenderness;
18. Cyanotic/red/pale digit/extremity;
19. Increased sweating;
20. Alteration of temperature;
21. Persistent loss of motion;
22. Trophic skin changes;
23. Flexion contractures;
24. Pain is chronic, refractory, and interferes with ADLs;
25. Failure of ≥ 6 months of conventional multidisciplinary therapy including all of the following:
26. Physical therapy or occupational therapy;
27. Anticonvulsant or antidepressant medication;
28. Sympathetic block;
29. Has demonstrated cognitive ability to manage stimulator;
30. No inadequately treated major psychiatric disorders;
31. Willingness to cease any inappropriate drug use prior to implantation.
32. *A trial of SCS* for *chronic ischemic leg pain due to peripheral vascular disease* when all of the following criteria are met:
33. Chronic, ischemic leg pain due to peripheral vascular disease and one of the following:
34. Not a candidate for revascularization;
35. Revascularization has failed to relieve painful symptoms and the pain has not responded to medical management;
36. Pain lasting ≥ 6 months, is refractory and interferes with ADLs;
37. Has demonstrated cognitive ability to manage stimulator;
38. No inadequately treated major psychiatric disorders;
39. Willingness to cease any inappropriate drug use prior to implantation.
40. *A trial of SCS* for *the following indications* has **limited evidence** to prove effectiveness of treatment and consideration will be made on a case by case basis. Medical necessity will be considered in members based on the following information:
41. Chronic, intractable pain due to one of the following:
42. Lumbosacral adhesive arachnoiditis secondary to multiple myelographies or lumbar surgeries that has not responded to medical management, including physical therapy (the presence of arachnoiditis is usually documented by the presence of high levels of proteins in the cerebro spinal fluid and/or by myelography or magnetic resonance imaging);
43. Nerve root injuries, post-surgical or post traumatic (e.g., avulsion);
44. Phantom limb syndrome that has not responded to medical management;
45. Post-herpetic neuralgia;
46. Plexopathy;
47. Polyneuropathy;
48. Intercostal neuralgia that did not respond to medical management and nerve blocks;
49. Cauda equina injury/syndrome;
50. Incomplete spinal cord injury;
51. Diabetic neuropathy;
52. Failed Neck Surgery Syndrome (FNSS)
53. Pain lasting ≥ 6 months, is refractory and interferes with ADLs;
54. Failure of≥ 6 months of conventional multidisciplinary medical therapy;
55. Has demonstrated cognitive ability to manage stimulator;
56. No inadequately treated major psychiatric disorders;
57. Willingness to cease any inappropriate drug use prior to implantation.
58. *A trial of SCS* for *refractory chronic stable angina pectoris* has **limited evidence** to prove effectiveness of treatment and consideration will be made on a case by case basis. It should be reserved only for carefully selected members, if any. Medical necessity will be considered in members based on the following information:
59. Continued angina after percutaneous coronary intervention or coronary artery bypass graft;
60. Not a candidate for further revascularization;
61. Angina is NYHA (New York Heart Association) III (less than ordinary physical activity causes symptoms) or IV (symptoms present at rest);
62. Reversible ischemia documented at least by a symptom-limited treadmill exercise test;
63. Has had optimal pharmacotherapy for at least one month that includes the maximal tolerated dose of at least 2 of the following:
    1. Long-acting nitrates;
    2. Beta-adrenergic blockers;
    3. Calcium channel antagonists;
64. Pain is chronic, refractory, and interferes with ADLs;
65. Has demonstrated cognitive ability to manage stimulator;
66. No inadequately treated major psychiatric disorders;
67. Willingness to cease any inappropriate drug use prior to implantation.
68. *Permanent placement of a SCS* is **medically necessary** following a trial of spinal cord stimulation for an indication listed above when all of the following criteria are met:
69. Disease specific criteria for spinal cord stimulation are met;
70. Documented trial of ≥ 3 days;
71. Documented pain reduction of > 50% from the trial associated with functional improvement;
72. The same device used for the trial is used for permanent placement.

## Background

SCS is currently used to treat a wide variety of inoperable and intractable chronic pain syndromes, including failed back surgery syndrome and CRPS. In patients with failed conservative and surgical treatment of lower-limb ischemia, SCS increases skin blood flow, decreases pain, and improves quality of life. Four studies used inferential statistics and found pain reduction to be significant. At least 50% pain reduction at follow-up was found in 78%, 80%, and 85% of patients in the three studies that reported this data. Follow-up ranged from 6 to 35 months.

According to recent systematic reviews, the most favorable results have been observed in patients with peripheral vascular disease, complex regional pain syndrome, and peripheral neuropathy (e.g., diabetic or causalgic origin). Of interest, the pain relief achieved with SCS in patients with complex regional pain syndrome is possible without vasodilation. The vasodilation found with SCS is attributed to an inhibitory effect on sympathetically maintained vasoconstriction. Diabetic patients with peripheral arterial occlusive disease who present with intractable pain have also been successfully treated with SCS, except those who have severe autonomic neuropathy. Recently, SCS has been successfully used to treat intractable angina pectoris and chronic mesenteric ischemia.

Spinal cord stimulation is proposed as a late or last resort treatment for chronic pain due to stable angina pectoris. Although most of the research reviewed used subjective outcome measures and some studies lacked prospective design, adequate sample size, and control groups, SCS was shown to alleviate pain and reduce myocardial ischemia in many of the study patients for whom pain relief was previously unobtainable. SCS has also been shown to reduce service utilization in aggregate among recipients. Side effects, while not infrequent, are rarely serious and can usually be resolved by the realignment or replacement of the device. Evidence indicates that the analgesic effect of SCS in angina does not mask the warning pain of myocardial infarction. Patients who have been treated with SCS have not been shown to be at increased risk for morbidity or mortality compared with their peers. Although a minority of patients receiving a trial of SCS ultimately experience prolonged pain relief, the significance of the alleviation of pain and suffering among those who do cannot be underestimated. Therefore, spinal cord stimulation for chronic stable angina pectoris secondary to demonstrable myocardial ischemia in patients who are refractory to treatment should be considered.

Slangen et al (2014) performed a multicenter randomized clinical trial in 36 painful diabetic peripheral neuropathy (PDPN) patients with severe lower limb pain not responding to conventional therapy. The authors concluded treatment success was shown in 59% of patients with PDPN who were treated with SCS over a 6-month period, although this treatment is not without risks. Two year outcomes of the same study reported clinically significant improvements in pain and sleep in 53% of patients. Additionally, a randomized controlled trial of 60 patients, conducted by de Vos and colleagues, found that pain due to PDPN was significantly reduced from baseline at 6 months, and quality of life was improved.

**Coding Implications**

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2019, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

| **CPT® Codes** | **Description** |
| --- | --- |
| 63650 | Percutaneous implantation of neurostimulator electrode array, epidural |
| 63655 | Laminectomy for implantation of neurostimulator electrodes, plate/paddle, epidural |
| 63685 | Incision and subcutaneous placement of spinal neurostimulator pulse generator or receiver, direct or inductive coupling |
| 95970 | Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain, cranial nerve, spinal cord, peripheral nerve, or sacral nerve, neurostimulator pulse generator/transmitter, without programming |
| 95971 | Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with simple spinal cord or peripheral nerve (eg, sacral nerve) neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional |
| 95972 | Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with complex spinal cord or peripheral nerve (eg, sacral nerve) neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional |

| **HCPCS Codes** | **Description** |
| --- | --- |
| L8679 | Implantable neurostimulator, pulse generator, any type |
| L8680 | Implantable neurostimulator electrode, each |
| L8681 | Patient programmer (external) for use with implantable programmable neurostimulator pulse generator, replacement only |
| L8682 | Implantable neurostimulator radiofrequency receiver |
| L8683 | Radiofrequency transmitter (external) for use with implantable neurostimulator radiofrequency receiver |
| L8685 | Implantable neurostimulator pulse generator, single array, rechargeable includes extension |
| L8686 | Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension |
| L8687 | Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension |
| L8688 | Implantable neurostimulator pulse generator, dual array, nonrechargeable, includes extension |

**ICD-10-CM Diagnosis Codes that Support Coverage Criteria**

| **ICD-10-CM Code** | **Description** |
| --- | --- |
| B02.29 | Other postherpetic nervous system involvement |
| E10.40 | Type 1 diabetes mellitus with diabetic neuropathy, unspecified |
| E10.41 | Type 1 diabetes mellitus with diabetic mononeuropathy |
| E10.42 | Type 1 diabetes mellitus with diabetic polyneuropathy |
| E10.43 | Type 1 diabetes mellitus with diabetic autonomic (poly) neuropathy |
| E10.49 | Type 1 diabetes mellitus with other diabetic neurological complication |
| E11.40 | Type 2 diabetes mellitus with diabetic neuropathy, unspecified |
| E11.41 | Type 2 diabetes mellitus with diabetic mononeuropathy |
| E11.42 | Type 2 diabetes mellitus with diabetic polyneuropathy |
| E11.43 | Type 2 diabetes mellitus with diabetic autonomic (poly) neuropathy |
| E11.49 | Type 2 diabetes mellitus with other diabetic neurological complication |
| G03.1 | Chronic meningitis |
| G09 | Sequelae of inflammatory diseases of central nervous system |
| G54.0-G54.9 | Nerve root and plexus disorders |
| G56.40-G56.42 | Causalgia of upper limb |
| G56.80-G56.82 | Other specified mononeuropathies of upper limb |
| G56.90-G56.93 | Unspecified mononeuropathies of upper limb |
| G57.70-G57.73 | Causalgia of lower limb |
| G57.80-G57.93 | Other specified mononeuropathies of lower limb |
| G90.50-G90.59 | Complex regional pain syndrome I (CRPSI) |
| I20.1 | Angina pectoris with documented spasm |
| I70.221-I70.229 | Atherosclerosis of native arteries of extremities with rest pain |
| I73.9 | Peripheral vascular disease, unspecified |
| M54.10 | Radiculopathy, site unspecified |
| M54.12 | Radiculopathy, cervical region |
| M54.13 | Radiculopathy, cervicothoracic region |
| M54.14 | Radiculopathy, thoracic region |
| M54.15 | Radiculopathy, thoracolumbar region |
| M54.16 | Radiculopathy, lumbar region |
| M54.17 | Radiculopathy, lumbosacral region |
| M54.30-M54.32 | Sciatica |
| M79.2 | Neuralgia and neuritis, unspecified |
| M96.1 | Postlaminectomy syndrome, not elsewhere classified |
| R20.3 | Hyperesthesia |
| S14.2XX\* | Injury of nerve root of cervical spine |
| S24.2XX\* | Injury of nerve root of thoracic spine |
| S34.21X\* | Injury of nerve root of lumbar spine |
| S34.22X\* | Injury of nerve root of sacral spine |
| S34.3XX\* | Injury of cauda equine |
| T87.9 | Unspecified complications of amputation stump |

\*Add 7th digit A-S

| **Reviews, Revisions, and Approvals** | **Date** | **Approval Date** |
| --- | --- | --- |
| Policy split from CP.MP.63 Pain Management Procedures.  Added chronic lower limb ischemia indication in I. C per Cochrane review of effectiveness. I.D. Case by-case indications: Added indications in I.D. per American Association of Neurological Surgeons 2008 information on SCS, and 2010 American Society of Anesthesiologists guidelines; added diabetic neuropathy indication. Added requirement for reversible ischemia documented by treadmill exercise test, per inclusion criteria in study by de Jongste. Added ICD-10 codes for diabetic neuropathy. | 07/16 | 07/16 |
| Took out requirement for more than 1 failed back surgery or failed back surgery at more than 1 level in failed back surgery syndrome (FBSS) indication (I.A.), as this was not supported by literature. Specified that pain in FBSS should be neuropathic. Added hyperalgesia as a symptom of CRPS. Coding updated. | 07/17 | 07/17 |
| References reviewed and updated. | 05/18 | 05/18 |
| Added Failed Neck Surgery Syndrome to indications under limited evidence criteria (I.D.1.k). Reviewed by specialist. | 9/18 | 09/18 |
| References reviewed and updated. Codes updated | 3/19 | 04/19 |

### References

1. Abdi S. Complex regional pain syndrome in adults: Pathogenesis, clinical manifestations and diagnosis. In: UptoDate, Shefner JM (Ed), UpToDate. Waltham, MA. Accessed 5/2/18.
2. Abdi S. Complex regional pain syndrome in adults: Prevention and management. In: UpToDate, Shefner JM (Ed), UpToDate. Waltham, MA. Accessed 5/2/18.
3. American Association of Neurological Surgeons (AANS). Patient Information >> Spinal Cord Stimulation. Available at: <http://www.aans.org/Patient%20Information/Conditions%20and%20Treatments/Spinal%20Cord%20Stimulation.aspx>. Accessed 5/7/18.
4. American Society of Anesthesiologists Task Force on Chronic Pain Management; American Society of Regional Anesthesia and Pain Medicine. Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine. Anesthesiology. 2010;112(4):810-833.
5. Cho JH, Lee JH, Song KS, et al. Treatment Outcomes for Patients with Failed Back Surgery. Pain Physician. 2017 Jan-Feb;20(1):E29-E43.
6. de Jongste MJ, Hautvast RW, Hillege HL, Lie KI. Efficacy of spinal cord stimulation as adjuvant therapy for intractable angina pectoris: A prospective, randomized clinical study. J Am Coll Cardiol. 1994;23(7):1592-1597.
7. de Vos CC, Meier K, Zaalberg PB, et al. Spinal cord stimulation in patients with painful diabetic neuropathy: a multicentre randomized clinical trial. Pain. 2014;155(11):2426-2431.
8. Hayes Medical Technology Directory. Electrical Spinal Cord Stimulation for the Treatment of Intractable Angina Pectoris. October 2014. Annual review September 13, 2017.
9. Hayes Medical Technology Directory. Spinal Cord Stimulation for Relief of Neuropathic Pain. October 2015. Annual review September 19, 2017.
10. McKenzie-Brown AM. Spinal cord stimulation: Placement and management. In: UpToDate. Fishman S (Ed), UpToDate. Waltham, MA. Accessed 5/7/18.
11. Petrakis IE, Sciacca V. Does autonomic neuropathy influence spinal cord stimulation therapy success in diabetic patients with critical lower limb ischemia? Surg Neurol. 2000;53:182-189.
12. Simmons M, Laham RJ. New therapies for angina pectoris. In: UpToDate, Kaski JC (Ed), UpToDate, Waltham, MA. Accessed 5/7/18.
13. Slangen R, Schaper NC, Faber CG, et al. Spinal cord stimulation and pain relief in painful diabetic peripheral neuropathy: a prospective two-center randomized controlled trial. Diabetes Care. 2014;37(11):3016-3024.
14. Tsigaridas N, Naka K, Tsapogas P, et al. Spinal cord stimulation in refractory angina. A systematic review of randomized controlled trials. Acta Cardiol. 2015 Apr;70(2):233-43.
15. Ubbinik DT, Vermeulen H. Spinal cord stimulation for non-reconstructable chronic critical leg ischaemia. Cochrane Database Syst Rev. 2013 Feb 28;(2):CD004001. doi: 10.1002/14651858.CD004001.pub3.
16. Van Beek M, Slangen R, Schaper NC et al. Sustained Treatment Effect of Spinal Cord Stimulation in Painful Diabetic Peripheral Neuropathy: 24-Month Follow-up of a Prospective Two-Center Randomized Controlled Trial. [Diabetes Care.](http://www.ncbi.nlm.nih.gov/pubmed/26116722) 2015 Sep;38(9):e132-4. doi: 10.2337/dc15-0740.

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note: For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

**Note: For Medicare members,** to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs, and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at <http://www.cms.gov> for additional information.

©2016 Centene Corporation. All rights reserved.  All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law.  No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.